CDMOs must consider challenges associated with the complexity of contract pharmaceutical manufacturing when approaching digitalization projects.
Kai Vogt
Advertisement
Kai Vogt is senior vice-president Corporate Development, Legal and Compliance, Information Technology at Vetter Pharma.
Articles by Kai Vogt
Advertisement
Latest Updated Articles
- Digitalization: A CDMO’s Perspective
Published: February 15th 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
